Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.
2.

Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.

Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT.

J Biol Chem. 2011 Apr 15;286(15):13626-37. doi: 10.1074/jbc.M110.216820. Epub 2011 Feb 16.

3.
4.

HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT.

Oncoimmunology. 2014 Dec 21;3(11):e956012. eCollection 2014 Nov.

5.

Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.

Vicari D, Foy KC, Liotta EM, Kaumaya PT.

J Biol Chem. 2011 Apr 15;286(15):13612-25. doi: 10.1074/jbc.M110.216812. Epub 2011 Feb 14.

6.

Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.

Garrett JT, Rawale S, Allen SD, Phillips G, Forni G, Morris JC, Kaumaya PT.

J Immunol. 2007 Jun 1;178(11):7120-31.

7.

IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.

Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PT.

Oncoimmunology. 2014 Dec 21;3(11):e956005. eCollection 2014 Nov.

8.

Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.

Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PT.

J Immunol. 2013 Jul 1;191(1):217-27. doi: 10.4049/jimmunol.1300231. Epub 2013 May 22.

9.

Immunization with synthetic VEGF peptides in ovarian cancer.

Wang B, Kaumaya PT, Cohn DE.

Gynecol Oncol. 2010 Dec;119(3):564-70. doi: 10.1016/j.ygyno.2010.07.037. Epub 2010 Sep 6.

10.

Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.

Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, Morris JC, Oshima RG, Kaumaya PT.

J Immunol. 2007 Jul 1;179(1):472-82.

11.

Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies.

Li W, Ran Y, Li M, Zhang K, Qin X, Xue X, Zhang C, Hao Q, Zhang W, Zhang Y.

BMC Biotechnol. 2013 Sep 27;13:77. doi: 10.1186/1472-6750-13-77.

12.

Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu.

Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E.

J Immunol. 2004 Jul 1;173(1):394-401.

13.

Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.

Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, Scheiner O, Zielinski CC, Wiedermann U.

Breast Cancer Res Treat. 2007 Nov;106(1):29-38. Epub 2007 Jan 3.

PMID:
17203384
15.

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).

Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT.

Vaccines (Basel). 2015 Jul 6;3(3):519-43. doi: 10.3390/vaccines3030519.

17.

Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.

Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT.

J Biol Chem. 2005 Jan 7;280(1):54-63. Epub 2004 Oct 26.

18.
19.

The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?

Koukourakis MI, Simopoulos C, Polychronidis A, Perente S, Botaitis S, Giatromanolaki A, Sivridis E.

Anticancer Res. 2003 Mar-Apr;23(2C):1673-80.

PMID:
12820439
20.

B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).

Zhu L, Zhao L, Wu M, Chen Z, Li H.

Immunol Lett. 2013 Jun;153(1-2):33-40. doi: 10.1016/j.imlet.2013.07.003. Epub 2013 Jul 18.

PMID:
23871733
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk